Compare Cassava Sciences Inc (FLNA) vs Sezzle Inc (SEZL) Price & Performance

FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.

The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.

Sezzle (SEZL) surged 9.98% to $125.21, reflecting strong momentum after consistently beating earnings estimates. The stock shows bullish technical signals with robust fundamentals including 51.7% revenue growth in Q2 2026 and exceptional profitability metrics (ROE 88.85%, net margin 30.35%). Recent product launches like Sezzle Send and SezzleCash are driving user growth and platform engagement.

Outlook remains positive with 35% revenue growth guidance and 35.9% upside to consensus price target of $168. Key risks include BNPL competition and potential credit quality concerns, but strong institutional buying and analyst optimism support the bullish case for continued growth.